Genetics

Christopher Counter, PhD, associate director of Basic Research, is a member of a group receiving an international Cancer Grand Challenges Grant to investigate origins of cancer.

DCI member and physician-scientist Sandeep Dave, MD, MS, has been named the Wellcome Clinical Distinguished Professor of Medicine.

A DCI breast cancer care team joins forces with a genetics counselor to treat mother with high-risk genetic syndrome; prompting testing and preventative screening for her kids.

DCI medical oncologists Angeles Alvarez Secord, MD, MHSc, and Rafael Gonzalez, MD, & genetics counselor Maggie Frazier, MS, CGC discussed ovarian cancer, in this DCI OHE event for the community. 

After 32 years with the Duke Cancer Institute family, breast medical oncologist P. Kelly Marcom, MD, retired from clinical practice at the end of May.

This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.

DCI faculty Michaela Dinan, PhD, on the impact of the Oncotype DX test on HR+ breast cancer patients over 65, treatment disparities, & the latest therapies.

Medical oncologist John Strickler, MD, and his patient Tom Vibert, a stage 4 colon cancer survivor, talk about the importance of biomarker testing.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

Duke University ranked eighth among the nation’s top medical schools and research institutions for funding from the NIH.

For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

Carolyn Menendez, MD, FACS, assistant professor of Surgical Oncology has been appointed director of Duke Cancer Institute’s Clinical Cancer Genetics Program.